GlassScriptPhysician profile
J Ruth Smith
NPI 1467178830
$1,317.70
in general payments reported to CMS, 2019-2025
17 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.16 · 2023: $301 · 2024: $612 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $709.80 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $137.64 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $102.27 | 2023-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $76.64 | 2023-2025 | |
| Glaxosmithkline, LLC. | $59.95 | 2025 | Trelegy Ellipta |
| Lundbeck LLC | $30.06 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $27.53 | 2023-2024 | Veozah |
| Inspire Medical Systems, INC. | $26.69 | 2024 | Inspire |
| Verona Pharma, INC. | $23.66 | 2025 | Ohtuvayre |
| Vertex Pharmaceuticals Incorporated | $18.37 | 2025 | |
| Vanda Pharmaceuticals INC. | $17.51 | 2025 | Fanapt |
| Mylan Specialty L.P. | $17.46 | 2024 | Yupelri |
| Exact Sciences Corporation | $16.84 | 2025 | The Cologuard Plus Collection Kit |
| Phadia US INC. | $14.99 | 2025 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.05 | 2024 | Xifaxan, Trulance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $12.16 | 2022 | |
| Axsome Therapeutics, INC. | $12.08 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw J Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.